Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study

Table 3 Characteristics of hepatitis C patients according to vaccine response

Characteristic	Non-responder(n = 10)	Low-responder(n = 8)	High-responder(n = 20)	P
Age (yr)	41.5 ± 11.3	46.1 ± 9.0	39.0 ± 10.1	0.394
Male/Female	8/2	5/3	17/3	0.417
BMI (kg/m2)	26.6 ± 6.0	24.9 ± 3.0	23.8 ± 4.6	0.903
Smoking n (%)	9 (90.0)	4 (50.0)	12 (60.0)	0.150
Alcohol n (%)	2 (20.0)	0 (0)	4 (20.0)	0.387
Hx of iv drug use n (%)	2 (20.0)	2 (25.0)	5 (25.0)	0.950
ALT (IU/L)	177.1 ± 293.9	149.8 ± 304.6	49.8 ± 40.3	0.711
Liver disease
HAI grade (0-18)	5.4 ± 2.1	5.4 ± 2.8	5.7 ± 1.3	0.607
HAI stage (0-6)	2.3 ± 1.1	2.4 ± 1.8	2.7 ± 1.5	0.986
HCV genotype n (%)	8	8	18
1a	6 (75.0)a	7 (87.5)a	7 (38.9)a	0.038
Other than 1a	2 (25.0)	1 (12.5)	11 (61.1)

Non-responder (anti-HBs < 10 IU/L); Low-responder (10 IU/L < anti-HBs < 100 IU/L); High-responder (anti-HBs > 100 IU/L).

^aP < 0.05 comparison between three groups.